Cardiac Marker Testing Market worth 3.50 Bn USD by 2021

Friday 28 October 2016, Amsterdam

The report, now available on ASDReports, "Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) - Global Forecast to 2021" , analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report studies the global cardiac marker testing market over the forecast period of 2016 to 2021. The market is expected to reach ~USD 3.50 Billion by 2021, at a CAGR of 8.8% from 2016 to 2021. A number of factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse systems are some of the key factors limiting the growth of the global cardiac marker testing market.

Based on type, the global cardiac marker testing market is divided into six segments, namely, troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment includes galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine.

On the basis of product, the global cardiac marker testing market is segmented into reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. On the basis of disease, the cardiac marker testing market is segmented into myocardial infarction and congestive heart failure. On the basis of type of testing, the cardiac marker testing market is segmented into laboratory testing and point-of-care testing.

As of 2016, North America held the largest share of the global cardiac marker testing market, followed by Europe. However, the Asia-Pacific market is expected to register the highest CAGR of 11.7% from 2016 to 2021. Factors such as rising prevalence and incidence of cardiovascular diseases and public-private initiatives to increase awareness about early cardiac disease diagnosis are stimulating the growth of the cardiac marker testing market in the Asia-Pacific region.

Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) (China) are some of the key players operating in the global cardiac marker testing market.